AR038287A1 - Composicion farmaceutica que comprende una glitazona y un acido 4-oxobutanoico y uso de la misma para el tratamiento de la diabetes - Google Patents

Composicion farmaceutica que comprende una glitazona y un acido 4-oxobutanoico y uso de la misma para el tratamiento de la diabetes

Info

Publication number
AR038287A1
AR038287A1 ARP030100058A ARP030100058A AR038287A1 AR 038287 A1 AR038287 A1 AR 038287A1 AR P030100058 A ARP030100058 A AR P030100058A AR P030100058 A ARP030100058 A AR P030100058A AR 038287 A1 AR038287 A1 AR 038287A1
Authority
AR
Argentina
Prior art keywords
group
aryl
alkyl
radical
groups
Prior art date
Application number
ARP030100058A
Other languages
English (en)
Inventor
Moinet Gerard Dr
Marais Dominique Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR038287A1 publication Critical patent/AR038287A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica, que comprende, como principios activos, (i) al menos una glitazona y (ii) al menos un compuesto de la fórmula (1), en asociación con uno o varios excipientes aceptables para uso farmacéutico, donde el compuesto de la fórmula (1) se define de la siguiente manera: los grupos A y B se seleccionan, independientemente entre sí, entre: un grupo arilo mono, bi o tricíclico que contiene entre 6 y 14 átomos de carbono; un grupo heteroaromático seleccionado entre grupos piridilo, pirimidilo, pirrolilo, furilo y tienilo; un grupo alquilo que contiene entre 1 y 14 átomos de carbono; un grupo cicloalquilo que contiene entre 5 y 8 átomos de carbono; un grupo heterocíclico saturado seleccionado entre grupos tetrahidrofurilo, tetrahidropiranilo, piperidilo y pirrolidinilo; donde los grupos A y B pueden llevar entre 1 y 3 sustituyentes seleccionados entre un grupo (C1-6) alquilo, (C1-6) alcoxi, (C6-14) arilo, heteroarilo seleccionado entre piridilo, pirimidilo, pirrolilo, furilo y tienilo, un grupo (C6-14) aril (C1-6) alquilo, (C6-14)aril(C1-6)alquil(C6-14)arilo, un halógeno, un grupo trifluorometilo, trifluorometoxi, ciano, hidroxilo, nitro, amino, carboxilo, (C1-6)alcoxicarbonilo, carbamoílo, (C1-6)alquilsulfonilo, sulfoamino, (C1-6)alquilsulfonilamino, sulfamoílo, (C1-6)alquilcarbonilamino; o dos de los sustituyentes forman un grupo metilendioxi, un solvato del mismo o una sal de este ácido. Reivindicación 2: La composición acorde con la reivindicación 1, caracterizada porque la glitazona es un compuesto que presenta la fórmula general (2), donde: E representa una estructura aromática monocíclica, bicíclica o tricíclica de base hidrocarbonada que puede incluir uno o varios heteroátomos, donde esta estructura puede estar opcionalmente sustituida con al menos un radical (C1-6) alquilo o acetilo o puede formar un anillo de 5 ó 6 miembros con el radical metileno unido a Y; N es igual a 1, 2 ó 3, Y representa un átomo de oxígeno, una función -NHCO-, -CONH- o -CO-; y F representa un grupo amino o un grupo de base hidrocarbonada aromático o no aromático, cíclico o bicíclico, que contiene optativamente un heteroátomo seleccionado entre oxígeno y nitrógeno, donde los grupos amino y de base hidrocarbonada pueden contener al menos una sustitución seleccionada entre un radical (C1-6) alquilo, un átomo de halógeno, un radical arilo o heteroarilo, un radical acetilo y un radical trifluorometilo, o una sal aceptable para uso farmacéutico de la misma.
ARP030100058A 2002-01-11 2003-01-10 Composicion farmaceutica que comprende una glitazona y un acido 4-oxobutanoico y uso de la misma para el tratamiento de la diabetes AR038287A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0200335A FR2834640B1 (fr) 2002-01-11 2002-01-11 Composition pharmaceutique comprenant une glitazone et un acide 4-oxobutanoique et son utilisation pour traiter le diabete

Publications (1)

Publication Number Publication Date
AR038287A1 true AR038287A1 (es) 2005-01-12

Family

ID=8871257

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100058A AR038287A1 (es) 2002-01-11 2003-01-10 Composicion farmaceutica que comprende una glitazona y un acido 4-oxobutanoico y uso de la misma para el tratamiento de la diabetes

Country Status (16)

Country Link
US (1) US20050085489A1 (es)
EP (1) EP1463503A1 (es)
JP (1) JP2005516963A (es)
KR (1) KR20040078109A (es)
CN (1) CN1599608A (es)
AR (1) AR038287A1 (es)
AU (1) AU2002361421A1 (es)
BR (1) BR0215498A (es)
CA (1) CA2473043A1 (es)
FR (1) FR2834640B1 (es)
HU (1) HUP0402645A2 (es)
MX (1) MXPA04006675A (es)
PL (1) PL370175A1 (es)
RU (1) RU2004124523A (es)
WO (1) WO2003057216A1 (es)
ZA (1) ZA200406329B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6346658B2 (ja) 2013-03-14 2018-06-20 ダート・ニューロサイエンス・（ケイマン）・リミテッド Ｍａｏ阻害剤としての置換ナフチリジン及びキノリン化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863915A (en) * 1996-05-15 1999-01-26 Bayer Corporation Substituted 4-arylbutyric acid derivatives as matrix metalloprotease
FR2752422B1 (fr) * 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GB9922710D0 (en) * 1999-09-24 1999-11-24 Bayer Ag Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
US20050085489A1 (en) 2005-04-21
CA2473043A1 (en) 2003-07-17
JP2005516963A (ja) 2005-06-09
WO2003057216A1 (en) 2003-07-17
KR20040078109A (ko) 2004-09-08
HUP0402645A2 (hu) 2005-07-28
MXPA04006675A (es) 2004-10-04
CN1599608A (zh) 2005-03-23
ZA200406329B (en) 2005-09-20
BR0215498A (pt) 2004-12-28
FR2834640B1 (fr) 2004-09-24
FR2834640A1 (fr) 2003-07-18
EP1463503A1 (en) 2004-10-06
PL370175A1 (en) 2005-05-16
RU2004124523A (ru) 2005-06-10
AU2002361421A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
AR102722A2 (es) Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit
AR015765A1 (es) Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento.
RU94039542A (ru) Производные пиперазина как антагонисты 5-нт-рецепторов, способ получения, фармацевтическая композиция
AR033408A1 (es) Compuestos de bisarilo que contienen nitrogeno orto, orto-sustituidos, procedimientos para su preparacion, su utilizacion para la preparacion de un medicamento como tambien composiciones farmaceuticas que los contienen
KR950704304A (ko) 이환식 헤테로환 함유 술폰아미드 및 술폰산 에스테르 유도체(bicyclic heterocyclic sulfonamide and sulfonic ester derivatives)
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
RU2003119153A (ru) Орто-, мета-замещенные бис-арильные соединения, способ их получения, их применение в качестве медикаментов, а также содержащие их фармацевтические композиции
RU2003121236A (ru) Арилированные амиды фуран- и тиофенкарбоновых кислот с блокирующим калиевый канал действием
EA200400480A1 (ru) N-замещённые производные пирролидина в качестве ингибиторов дипептидилпептидазы
UY28805A1 (es) Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso par tratar la diabetes y trastornos relacionados
RU2003100504A (ru) Органические соединения
BR0212829A (pt) Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
RU2002111561A (ru) 2'-замещенные 1,1'-бифенил-2-карбонамиды, способы их получения, их применение в качестве лекарственного средства, а также содержащие их фармацевтические композиции
RU2003120080A (ru) Орто-замещенные азотсодержащие бисарильные соединения для применения в качестве ингибиторов калиевого канала, а также содержащие их фармацевтические композиции
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
AR036600A1 (es) Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido [1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h) ona sustituidos
KR880009936A (ko) 피리딘-2,4-및-2,5-디카복실산 아미드, 그의 제조방법 및 용도
BRPI0408727A (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar de uma condição ou estado de doença mediados pela atividade da quinase p38 ou mediados pelas citocinas produzidas pela atividade da quinase p38, e, uso de um composto
RU2017117559A (ru) Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение
EA200970364A1 (ru) Новые производные имидазолонов в качестве лекарственных средств, способ их получения, фармацевтические композиции и применение в качестве ингибиторов протеинкиназ, в частности, cdc7
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
DK1216245T3 (da) Farmaceutisk aktive sulfonylhydrazidderivater
HUP0004223A2 (hu) 4-Oxo-butánsav-származékok és ezeket hatóanyagként tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
FB Suspension of granting procedure